Prof. Andrew Scott is Director, Department of Molecular Imaging and Therapy, Austin Health; leads the Tumour Targeting Program at the Olivia Newton-John Cancer Research Institute; and is Professor, University of Melbourne and La Trobe University in Melbourne, Australia.

Prof Scott's clinical and research interests are focused on developing innovative strategies for targeted therapy of cancer, and molecular imaging and theranostics in oncology. There have been seven antibodies developed in his laboratory have been licenced to Biotech and Pharma companies, and have entered Phase I/II/III trials. Prof Scott led the first trials of targeted therapeutics against FAP and numerous other cancer targets, and has been a pioneer of molecular targeting and therapy of cancer. He was the PI of Phase II multi-centre trials of FDG PET involving over 30,000 patients that have directly led to Medicare approval of PET in cancer patients.

As past-President of the World Federation of Nuclear Medicine and Biology, he has also been a strong advocate for global patient access to molecular imaging and therapeutics. ?He has received many awards, including Member of the Order of Australia (AM), election as Fellow of the Australian Academy of Health and Medical Sciences, the Lackmann Award for Translational Research, and the Saul Hertz Award from SNMMI (USA). Prof Scott has published 456 peer reviewed papers and 27 book chapters, is an inventor on 27 patents, and has received over $35 million in peer reviewed grant funding in the last 5 years.